View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 11, 2022

Odyssey reports positive data from Phase I concussion trial

According to the safety findings, PRV-002 was found to be safe and well tolerated in this cohort.

Odyssey Health has reported positive data from Cohort I of the multi-day ascending dosing (MAD) arm of the Phase I clinical trial analysing its new drug, PRV-002, to treat concussion.

The Phase I MAD trial is underway evaluating PRV-002 in 16 healthy human participants. 

It is being carried out by clinical research organisation Avance Clinical, through Nucleus Network, which is a Phase I trial provider with various sites in Australia. 

Previously, the Phase I SAD arm of the drug was completed and found to be well-tolerated.

MAD Cohort I participants received the drug for five successive days. 

Cohort I of MAD enrolled eight subjects, who received one low intranasal dose of PRV-002 and underwent subsequent analyses for abnormal responses. 

According to the safety findings, PRV-002 was found to be safe and well tolerated in this cohort.

Furthermore, no severe adverse events were reported.

A synthetic neurosteroid, PRV-002 is being developed to treat mTBI (concussion). 

PRV-002 showed neuroprotective effects in line with, if not superior to neurosteroids in preclinical studies. 

In animal concussion models, PRV-002 was found to lower the behavioural pathology linked to brain injury symptoms such as impairment in memory, motor/sensory performance and anxiety. 

Odyssey Health drug development head Dr Jacob VanLandingham said: “PRV-002 appears to be well-tolerated when given intranasally. 

“If PRV-002 is found to be efficacious for concussed patients in the Phase II/III trials, I believe that intranasal brain-targeting will be the key to its success. 

“So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena